Full metadata record
DC FieldValueLanguage
dc.contributor.authorChen, Yun-Juen_US
dc.contributor.authorKay, Narien_US
dc.contributor.authorYang, Jinn-Moonen_US
dc.contributor.authorLin, Chih-Taen_US
dc.contributor.authorChang, Hsueh-Lingen_US
dc.contributor.authorWu, Yang-Changen_US
dc.contributor.authorFu, Chi-Fengen_US
dc.contributor.authorChang, Yuen_US
dc.contributor.authorLo, Stevenen_US
dc.contributor.authorHou, Ming-Fengen_US
dc.contributor.authorLee, Yi-Chenen_US
dc.contributor.authorHsieh, Ya-Chingen_US
dc.contributor.authorYuan, Shyng-Shiouen_US
dc.date.accessioned2014-12-08T15:31:17Z-
dc.date.available2014-12-08T15:31:17Z-
dc.date.issued2013-07-01en_US
dc.identifier.issn1742-7835en_US
dc.identifier.urihttp://dx.doi.org/10.1111/bcpt.12057en_US
dc.identifier.urihttp://hdl.handle.net/11536/22263-
dc.description.abstractFlavonoids have been intensively explored for their anticancer activity. In this study, a total synthetic flavonoid protoapigenone, known as WYC02, was analysed for its potential anticancer activity on human cervical cancer cells as well as the underlying mechanisms for these effects. The site-moiety maps are used to explore the binding site similarity, pharmacophore and docking pose similarity. The effect of WYC02 on cell viability, migration, invasion and apoptosis as well as the underlying mechanisms was analysed in vitro using human cervical cancer cells. The effect of WYC02 on in vivo tumour growth was assessed in a tumour xenograft study. WYC02 inhibited cell proliferation, MMPs activity, migration and invasion in cervical cancer cells. We speculated that WYC02 might inhibit the activities of PIK3 family proteins, including PIK3CA, PIK3CB, PIK3CD and PIK3CG. Indeed, WYC02 decreased the expression of PIK3 family proteins, especially PIK3CG, through ubiquitination and inhibited the activities of PIK3CG and PIK3 downstream molecules AKT1 and MTOR in cervical cancer cells. Furthermore, PIK3 signalling pathway was involved in the inhibitory effect of WYC02 on cervical cancer cell proliferation and tumour growth in vitro and in vivo. WYC02 inhibits cervical cancer cell proliferation and tumourigenesis via PIK3 signalling pathway and has the potential to be developed as a chemotherapeutic agent in cervical cancer.en_US
dc.language.isoen_USen_US
dc.titleTotal Synthetic Protoapigenone WYC02 Inhibits Cervical Cancer Cell Proliferation and Tumour Growth through PIK3 Signalling Pathwayen_US
dc.typeArticleen_US
dc.identifier.doi10.1111/bcpt.12057en_US
dc.identifier.journalBASIC & CLINICAL PHARMACOLOGY & TOXICOLOGYen_US
dc.citation.volume113en_US
dc.citation.issue1en_US
dc.citation.spage8en_US
dc.citation.epage18en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.department生物資訊及系統生物研究所zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.contributor.departmentInstitude of Bioinformatics and Systems Biologyen_US
dc.identifier.wosnumberWOS:000320392300002-
dc.citation.woscount2-
Appears in Collections:Articles


Files in This Item:

  1. 000320392300002.pdf

If it is a zip file, please download the file and unzip it, then open index.html in a browser to view the full text content.